title: Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.
authors.affiliation: Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
authors.forename: Aiden
authors.initials: A
authors.lastname: Haghikia
authors.affiliation: Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
authors.forename: Calliope A
authors.initials: CA
authors.lastname: Dendrou
authors.affiliation: Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
authors.forename: Ruth
authors.initials: R
authors.lastname: Schneider
authors.affiliation: Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Grüter
authors.affiliation: Neurologic Clinic, St Vincenz-Krankenhaus, Paderborn, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Postert
authors.affiliation: Department of Neurology of the University of Magdeburg, Magdeburg, Germany.
authors.forename: Mike
authors.initials: M
authors.lastname: Matzke
authors.affiliation: Department of Neurology of the University of Magdeburg, Magdeburg, Germany.
authors.forename: Heike
authors.initials: H
authors.lastname: Stephanik
authors.affiliation: Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
authors.forename: Lars
authors.initials: L
authors.lastname: Fugger
authors.affiliation: Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany. Electronic address: ralf.gold@rub.de.
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
mesh_terms: D000328:Adult; D000074323:Alemtuzumab / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D001402:B-Lymphocytes / Q000276:immunology; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000276:immunology; D002493:Central Nervous System Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D012720:Severity of Illness Index
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000074323:Alemtuzumab